Addinex Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
8
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$306K
- Investors
-
6
Addinex General Information
Description
Developer of a low-cost pill dispensing system and application intended to reduce medication misuse and addiction. The company's patented dispenser and application limit dosage access, monitor treatment, ease medication disposal, and do not allow a patient to access the next pill until the minimum time interval has passed based on the prescription, helping healthcare professionals to prevent prescription drug misuse.
Contact Information
Website
www.addinextech.comCorporate Office
- 710 West 173rd Street
- Apartment 58
- New York, NY 10032
- United States
Corporate Office
- 710 West 173rd Street
- Apartment 58
- New York, NY 10032
- United States
Addinex Timeline
Addinex Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Grant | 17-Jul-2025 | $306K | Completed | Generating Revenue | ||
| 8. Grant | 01-Oct-2024 | Completed | Generating Revenue | |||
| 7. Grant | 05-Sep-2024 | Completed | Generating Revenue | |||
| 6. Accelerator/Incubator | 05-Sep-2023 | Completed | Generating Revenue | |||
| 5. Accelerator/Incubator | 18-May-2023 | Completed | Generating Revenue | |||
| 4. Grant | 07-Sep-2022 | Completed | Generating Revenue | |||
| 3. Angel (individual) | 15-Apr-2022 | Completed | Generating Revenue | |||
| 2. Accelerator/Incubator | 19-Jan-2022 | $550K | Completed | Generating Revenue | ||
| 1. Seed Round | 12-Mar-2021 | $550K | $550K | Completed | Startup |
Addinex Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Addinex Patents
Addinex Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-10335349-B2 | Prescription drug abuse prevention system | Active | 20-Jun-2017 | ||
| US-20180360693-A1 | Prescription drug abuse prevention system | Active | 20-Jun-2017 | ||
| WO-2018236865-A1 | Prescription drug abuse prevention system | Inactive | 20-Jun-2017 | A61J7/0076 |
Addinex Signals
Addinex Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Empire State Development | Government | |||
| National Institute on Drug Abuse (NIDA) | Government | |||
| NYC Innovation Hot Spot | Accelerator/Incubator | |||
| Community Safety & Wellness Accelerator | Accelerator/Incubator | |||
| United States Centers for Disease Control and Prevention | Government |
Addinex FAQs
-
When was Addinex founded?
Addinex was founded in 2017.
-
Where is Addinex headquartered?
Addinex is headquartered in New York, NY.
-
What is the size of Addinex?
Addinex has 8 total employees.
-
What industry is Addinex in?
Addinex’s primary industry is Other Devices and Supplies.
-
Is Addinex a private or public company?
Addinex is a Private company.
-
What is Addinex’s current revenue?
The current revenue for Addinex is .
-
How much funding has Addinex raised over time?
Addinex has raised $832K.
-
Who are Addinex’s investors?
Empire State Development, National Institute on Drug Abuse (NIDA), NYC Innovation Hot Spot, Community Safety & Wellness Accelerator, and United States Centers for Disease Control and Prevention are 5 of 6 investors who have invested in Addinex.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process